H. Grønbæk

发表

Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial

H. Møller, N. Møller, N. Jessen, 2017, Endocrine connections.

The damage‐associated molecular pattern HMGB1 is elevated in human alcoholic hepatitis, but does not seem to be a primary driver of inflammation

T. Sandahl, H. Grønbæk, H. Vilstrup, 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Effect of Combination Therapy with a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor on Renal Hypertrophy and Urinary Albumin Excretion in Diabetic Rats

H. Grønbæk, A. Flyvbjerg, R. Østerby, 2003, Experimental diabesity research.

Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study

H. Grønbæk, G. Villadsen, Abdullah Ghassan Muhammad, 2022, International journal of circumpolar health.

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis

H. Møller, H. Grønbæk, J. George, 2021, Frontiers in Medicine.

Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study

E. Horváth-Puhó, H. Sørensen, H. Grønbæk, 2009, The American Journal of Gastroenterology.

The Role of Growth Factors in Diabetic Kidney Disease

H. Grønbæk, A. Flyvbjerg, I. Vogel, 1996 .

The macrophage‐related biomarkers sCD163 and sCD206 are released by different shedding mechanisms

S. Moestrup, H. Møller, N. Rittig, 2019, Journal of leukocyte biology.

Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea

S. Laurberg, A. Drewes, T. Gregersen, 2016, Journal of neurogastroenterology and motility.

Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease

N. Geiker, H. Grønbæk, F. Magkos, 2021, Current Obesity Reports.

Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?

H. Grønbæk, J. George, Mikkel Breinholt Kjær, 2020, Expert review of gastroenterology & hepatology.

Markers of fetal growth and serum levels of insulin-like growth factor (IGF) I, -II and IGF binding protein 3 in adults

H. Sørensen, T. Lauritzen, M. Engberg, 2004, European Journal of Epidemiology.

Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease

H. Møller, A. Alisi, H. Grønbæk, 2018, Journal of pediatric gastroenterology and nutrition.

Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease.

A. Gastaldelli, H. Grønbæk, J. George, 2019, Journal of hepatology.

Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease

H. Møller, H. Grønbæk, E. Bugianesi, 2020, Frontiers in Medicine.

Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.

E. Riboli, A. Tjønneland, K. Overvad, 2012, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

F. Berrino, E. Riboli, A. Tjønneland, 2007, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Long‐Term Ethanol Exposure Decreases the Endotoxin‐Induced Hepatic Acute Phase Response in Rats

S. Hamilton-Dutoit, H. Grønbæk, H. Vilstrup, 2017, Alcoholism, clinical and experimental research.

Serum C‐peptide, IGFBP‐1 and IGFBP‐2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition

F. Clavel-Chapelon, F. Berrino, E. Riboli, 2007, International journal of cancer.

Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center

T. Sandahl, H. Grønbæk, G. Villadsen, 2016, Acta radiologica.

A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC)

I. Gram, F. Clavel-Chapelon, F. Berrino, 2011, Annals of human biology.

Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD

H. Grønbæk, T. L. Laursen, K. Kazankov, 2017, Current Hepatology Reports.

von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.

B. Stausbøl‐Grøn, L. Ousager, L. Sunde, 2022, European journal of medical genetics.

Effects of ischemic pre- and postconditioning on HIF-1α, VEGF and TGF-β expression after warm ischemia and reperfusion in the rat liver

P. Funch‐jensen, J. Frystyk, A. Knudsen, 2011, Comparative hepatology.

The Calcium Channel Blocker Nitrendipine Attenuates Renal and Glomerular Hypertrophy in Diabetic Rats

H. Grønbæk, A. Flyvbjerg, R. Østerby, 1999, Nephron Experimental Nephrology.

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours

H. Sorbye, J. Mortensen, M. Välimäki, 2010, Acta oncologica.

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

E. Baudin, T. Meyer, J. Mazières, 2017, The Lancet. Oncology.

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

H. Sorbye, H. Grønbæk, U. Knigge, 2018, Medical Oncology.

Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition

F. Clavel-Chapelon, E. Riboli, P. Vineis, 2012, British Journal of Cancer.

The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease

J. Dahlerup, J. Frystyk, H. Grønbæk, 2007, Scandinavian journal of gastroenterology.

Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women

F. Clavel-Chapelon, E. Riboli, A. Tjønneland, 2007, European Journal of Clinical Nutrition.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

H. Sorbye, J. Scoazec, J. Arola, 2017, PloS one.

Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes

S. Moestrup, H. Møller, H. Grønbæk, 2016, Molecular therapy. Methods & clinical development.

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

H. Sorbye, J. Mortensen, A. Sundin, 2014, Acta oncologica.

The role of IFN in the development of NAFLD and NASH.

H. Grønbæk, J. George, M. Eslam, 2019, Cytokine.

The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition.

I. Gram, F. Clavel-Chapelon, F. Berrino, 2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Serum levels of IGF‐I, IGFBP‐3 and colorectal cancer risk: results from the EPIC cohort, plus a meta‐analysis of prospective studies

F. Clavel-Chapelon, E. Riboli, P. Vineis, 2010, International journal of cancer.

Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis

J. Frystyk, H. Grønbæk, A. Flyvbjerg, 2002, Scandinavian journal of clinical and laboratory investigation.

Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience

H. Grønbæk, H. Vilstrup, N. Aagaard, 2013, Scandinavian journal of gastroenterology.

Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt.

H. Grønbæk, P. Holland‐Fischer, H. Vilstrup, 2013, World journal of hepatology.

β-Blockers Improve Presinusoidal Portal Hypertension

H. Grønbæk, H. Vilstrup, N. Aagaard, 2018, Digestive Diseases and Sciences.

Albumin in vaginal fluid is a marker of infection in early pregnancy

H. Grønbæk, A. Flyvbjerg, I. Vogel, 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease

M. Karsdal, P. Olinga, H. Grønbæk, 2020, Journal of clinical gastroenterology.

Non‐alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats

H. Grønbæk, J. George, H. Vilstrup, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Unchanged capacity of urea synthesis during acute phase response in rats

J. Frystyk, N. Jessen, H. Grønbæk, 2011, European journal of clinical investigation.

Tumor necrosis factor-α acutely up-regulates urea synthesis in vivo in rats – a hepatic component of inflammatory catabolism?

J. Frystyk, T. Sandahl, H. Grønbæk, 2010, Scandinavian journal of clinical and laboratory investigation.

Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center

H. Grønbæk, T. L. Laursen, Mikkel Breinholt Kjær, 2022, Journal of clinical medicine.

Ascites from patients with alcoholic liver cirrhosis contains higher IGF‐I bioactivity than serum

J. Frystyk, H. Grønbæk, A. Flyvbjerg, 2010, Clinical endocrinology.

Impact of Enteral Supplements Enriched with ω–3 Fatty Acids and/or ω–6 Fatty Acids, Arginine and Ribonucleic Acid Compounds on Leptin Levels and Nutritional Status in Active Crohn’s Disease Treated with Prednisolone

I. Brandslund, P. Munkholm, H. Grønbæk, 2007, Digestion.

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

J. Holst, Signe Foghsgaard, T. Vilsbøll, 2020, Journal of clinical medicine.

Crosstalk between adipose tissue insulin resistance and liver macrophage activation in patients with Non-Alcoholic Fatty Liver Disease

H. Møller, A. Gastaldelli, H. Grønbæk, 2020 .

Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability

H. Grønbæk, U. Lassen, M. Ladekarl, 2013, TheScientificWorldJournal.

Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis

J. Jelsing, N. Vrang, F. Knop, 2020, BMC Gastroenterology.

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial

M. Karsdal, H. Møller, H. Grønbæk, 2018, PloS one.

Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease.

S. B. Pedersen, H. Grønbæk, H. Stødkilde-Jørgensen, 2016, The Journal of clinical endocrinology and metabolism.

Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes

J. Rungby, H. Grønbæk, O. Schmitz, 2008, Expert review of gastroenterology & hepatology.

The Role of Growth Hormone, Insulin-Like Growth Factors, Epidermal Growth Factor and Transforming Growth Factor β in Diabetic Kidney Disease: An Update

Birgitte Lund Nielsen, A. Logan, H. Grønbæk, 1998 .

The presence of interferon affects the progression of non-alcoholic fatty liver disease

H. Grønbæk, T. L. Laursen, R. Hartmann, 2022, Genes & Immunity.

Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease

D. Schuppan, S. Hamilton-Dutoit, H. Grønbæk, 2018, PloS one.

Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function.

N. Jessen, H. Grønbæk, J. George, 2014, American journal of physiology. Gastrointestinal and liver physiology.

Effect of a 10-week Weight Loss Camp on Fatty Liver Disease and Insulin Sensitivity in Obese Danish Children

H. Grønbæk, P. Holland‐Fischer, H. Vilstrup, 2012, Journal of pediatric gastroenterology and nutrition.

Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional

H. Grønbæk, D. Granberg, J. Florholmen, 2012, Patient preference and adherence.

No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation

T. Sandahl, H. Grønbæk, H. Vilstrup, 2021, Clinical and translational gastroenterology.

The Renal Expression of Transforming Growth Factor-β Isoforms and Their Receptors in Acute and Chronic Experimental Diabetes in Rats.

J. Petrik, D. Hill, A. Logan, 2000, Endocrinology.

Serum Trefoil Factors in Patients with Inflammatory Bowel Disease

H. Grønbæk, E. Nexo, J. Nielsen, 2006, Digestion.

Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma

S. Hamilton-Dutoit, H. Grønbæk, J. Kelsen, 2020, BMC cancer.

Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).

S. Moestrup, H. Møller, V. Arroyo, 2016, Journal of hepatology.

The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men.

J. Rehfeld, M. Gillum, H. Møller, 2020, Alcohol.

The galactose elimination capacity test to monitor liver disease course in patients with Wilson’s disease

P. Ott, H. Grønbæk, H. Vilstrup, 2022, Scandinavian journal of gastroenterology.

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson’s disease

William M. Lee, H. Møller, T. Sandahl, 2020, Orphanet Journal of Rare Diseases.

Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with ω-3 or ω-6 fatty acids and corticosteroids

I. Brandslund, J. Frystyk, P. Munkholm, 2005 .

Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C

H. Møller, T. Sandahl, H. Grønbæk, 2020, Journal of viral hepatitis.

Metabolic Changes in the Pigliver During Warm Ischemia and Reperfusion Measured by Microdialysis

P. Funch‐jensen, F. Mortensen, H. Grønbæk, 2008, Journal of Gastrointestinal Surgery.

Partial Liver Ischemia Is Followed by Metabolic Changes in the Normally Perfused Part of the Liver during Reperfusion

P. Funch‐jensen, F. Mortensen, H. Grønbæk, 2010, European Surgical Research.

Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease

H. Møller, H. Grønbæk, T. L. Laursen, 2022, Expert opinion on therapeutic targets.

Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors

H. Sorbye, A. Sundin, H. Grønbæk, 2019, Neuroendocrinology.

Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients

A. Knudsen, H. Grønbæk, G. Dam, 2022, Frontiers in Endocrinology.

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study

H. Sorbye, H. Grønbæk, I. Gladhaug, 2016, Annals of Surgical Oncology.

Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study

S. Hamilton-Dutoit, H. Møller, S. Thiel, 2014, The American Journal of Gastroenterology.

Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study

H. Grønbæk, G. Villadsen, A. H. Madsen, 2018, Annals of Surgical Oncology.

Fibrosis is not just fibrosis – basement membrane modelling and collagen metabolism differs between hepatitis B‐ and C‐induced injury

M. Karsdal, D. Schuppan, A. Krag, 2016, Alimentary pharmacology & therapeutics.

Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites

H. Grønbæk, H. Vilstrup, Marianne Geilswijk, 2015, Scandinavian journal of gastroenterology.

Effects of five different alcoholic drinks on patients with Crohn's disease

H. Grønbæk, A. A. Nielsen, A. Schmedes, 2007, Scandinavian journal of gastroenterology.

Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease

S. Moestrup, H. Møller, T. Sandahl, 2017 .

Goblet Cell Carcinoids of the Appendix

H. Grønbæk, N. Holt, 2013, TheScientificWorldJournal.

High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study

H. Møller, T. Sandahl, P. Ott, 2018, Orphanet Journal of Rare Diseases.

Soluble CD163, a Specific Macrophage Activation Marker, is Decreased by Anti‐TNF‐α Antibody Treatment in Active Inflammatory Bowel Disease

H. Møller, J. Dahlerup, H. Grønbæk, 2014, Scandinavian journal of immunology.

Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases

S. Thiel, A. Hansen, M. Vesterhus, 2022, Journal of clinical and translational hepatology.

Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis

T. Karlsen, K. Boberg, H. Møller, 2021, Clinical and translational gastroenterology.

Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis.

T. Sandahl, H. Grønbæk, H. Vilstrup, 2020, American journal of physiology. Gastrointestinal and liver physiology.

Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease

H. Møller, H. Grønbæk, M. Andersen, 2020, Scandinavian journal of gastroenterology.

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial

M. Achiam, H. Møller, A. Steensberg, 2019, EBioMedicine.

Single‐centre experience of the macrophage activation marker soluble (s)CD163 – associations with disease activity and treatment response in patients with autoimmune hepatitis

S. Hamilton-Dutoit, T. Sandahl, N. Jessen, 2016, Alimentary pharmacology & therapeutics.

Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms’ Tumor in Childhood

S. Hamilton-Dutoit, H. Grønbæk, P. Kræmer, 2018, Case Reports in Gastroenterology.

The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease.

H. Grønbæk, J. George, M. Eslam, 2020, Trends in genetics : TIG.

Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease

A. Bauman, H. Grønbæk, J. George, 2017, Scandinavian journal of clinical and laboratory investigation.

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure

H. Møller, J. Trebicka, H. Grønbæk, 2020, Cells.

Trefoil factors in inflammatory bowel disease.

H. Grønbæk, E. Vestergaard, Luise Aamann, 2014, World journal of gastroenterology.

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

H. Sorbye, J. Arola, H. Grønbæk, 2020, PloS one.

Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease

N. Heegaard, J. Dahlerup, A. Handberg, 2013, Archives of physiology and biochemistry.

Regulation of urea synthesis during the acute-phase response in rats.

J. Holst, N. Jessen, H. Grønbæk, 2013, American journal of physiology. Gastrointestinal and liver physiology.

IL-6 has no acute effect on the regulation of urea synthesis in vivo in rats

J. Holst, J. Frystyk, N. Jessen, 2011, Scandinavian journal of clinical and laboratory investigation.

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

D. Schuppan, H. Møller, H. Grønbæk, 2018, Nature Reviews Gastroenterology & Hepatology.

The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease

B. Bibby, H. Møller, H. Grønbæk, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Editorial: measuring inflammatory and fibrotic components of portal hypertension – a non‐invasive hepatic venous pressure gradient? Authors’ reply

H. Møller, T. Sandahl, H. Grønbæk, 2016, Alimentary pharmacology & therapeutics.

Hepatic macrophage activation predicts clinical decompensation in chronic liver disease

H. Møller, P. Angus, D. Liew, 2013, Gut.

Prognosis of Patients with Bronchopulmonary Neuroendocrine Neoplasms in a Tertiary Neuroendocrine Tumor Centre of Excellence

H. Grønbæk, G. Dam, E. Tabaksblat, 2022, Neuroendocrinology.

Macrophage activation marker soluble CD163 and non‐alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery

K. Clément, H. Møller, P. Bedossa, 2015, Journal of gastroenterology and hepatology.

Prednisolone but Not Infliximab Aggravates the Upregulated Hepatic Nitrogen Elimination in Patients with Active Inflammatory Bowel Disease

L. A. Christensen, J. Dahlerup, J. Frystyk, 2014, Inflammatory bowel diseases.

The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children

H. Møller, A. Handberg, H. Grønbæk, 2015, Pediatric obesity.

Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention

H. Grønbæk, H. Vilstrup, H. Larsen, 2007, BMC gastroenterology.

Cytokine Changes during Warm Ischemia and Reperfusion of the Pig Liver with or without Preconditioning

P. Funch‐jensen, F. Mortensen, H. Grønbæk, 2009, European Surgical Research.

Macrophage markers and innate immunity in cirrhosis.

H. Møller, H. Grønbæk, T. L. Laursen, 2020, Journal of hepatology.

The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation

H. Møller, H. Grønbæk, F. Bendtsen, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Quality improvement in wellness reports in patients with Crohn’s disease

P. H. Petersen, I. Brandslund, H. Grønbæk, 2006 .

Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment.

J. Dahlerup, J. Frystyk, H. Grønbæk, 2002 .

Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment

J. Dahlerup, J. Frystyk, H. Grønbæk, 2002, American Journal of Gastroenterology.

Discharge diagnoses of liver diseases in Nuuk Greenland compared to a Danish county hospital

H. Grønbæk, H. Vilstrup, H. Pedersen, 2006, International journal of circumpolar health.

Carvedilol or propranolol in portal hypertension? A randomized comparison

H. Grønbæk, F. Bendtsen, S. Møller, 2012, Scandinavian journal of gastroenterology.

Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: A Danish population-based case-control study

H. Sørensen, H. Grønbæk, H. Vilstrup, 2008, BMC gastroenterology.

Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis

H. Grønbæk, L. Gluud, N. Aagaard, 2022, World journal of hepatology.

Advancing the global public health agenda for NAFLD: a consensus statement

Myeong Jun Song, R. Malekzadeh, V. Wong, 2021, Nature Reviews Gastroenterology & Hepatology.

Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course

T. Sandahl, H. Grønbæk, H. Vilstrup, 2013, PloS one.

Effect of resveratrol on experimental non-alcoholic steatohepatitis.

N. Jessen, H. Grønbæk, J. George, 2015, Pharmacological research.

The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients

H. Møller, T. Sandahl, H. Grønbæk, 2017, PloS one.

The Prevalence of Inflammatory Bowel Disease in Greenland.

A. Haase, H. Grønbæk, A. J. Petersen, 2023, Inflammatory bowel diseases.

The Insulin-Like Growth Factor System and Markers of Inflammation in Adult Patients with Inflammatory Bowel Disease

H. Grønbæk, A. Flyvbjerg, J. Nielsen, 2005, Hormone Research in Paediatrics.

A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors

E. Ingelsson, L. Lind, J. Dumanski, 2017, Endocrine-related cancer.

The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment.

J. Frystyk, J. Jørgensen, H. Grønbæk, 2015, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis

S. Hamilton-Dutoit, J. Nyengaard, M. Meier, 2018, World journal of hepatology.

No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion

H. Grønbæk, F. Bendtsen, J. Clemmesen, 2013, Liver international : official journal of the International Association for the Study of the Liver.

Quantitative histological assessment of hepatic ischemia-reperfusion injuries following ischemic pre- and post-conditioning in the rat liver.

J. Nyengaard, P. Funch‐jensen, A. Knudsen, 2013, The Journal of surgical research.

Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients

A. Kjær, H. Grønbæk, U. Knigge, 2014, PloS one.

Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma

H. Møller, P. Angus, D. Liew, 2016, Scandinavian journal of clinical and laboratory investigation.

IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis

D. Booth, T. Berg, A. Mangia, 2017, Nature Genetics.

Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C

B. Bibby, H. Møller, H. Grønbæk, 2014, Hepatology.

Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis

N. Jessen, H. Grønbæk, H. Vilstrup, 2017, Scandinavian journal of gastroenterology.

T. Sandahl, H. Grønbæk, J. George, 2020, World journal of gastroenterology.

Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.

J. Jelsing, N. Vrang, T. Vilsbøll, 2019, American journal of physiology. Gastrointestinal and liver physiology.

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

V. Wong, S. Wild, J. Lazarus, 2021, Hepatology.

Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS

S. Moestrup, H. Møller, T. Sandahl, 2011, Gut.

Urea cycle dysregulation in non-alcoholic fatty liver disease.

S. Hamilton-Dutoit, V. Felipo, R. Jalan, 2018, Journal of hepatology.

Enrichment of Genetic Variants in the Glucocorticoid Receptor Signalling Pathway in Autoimmune Hepatitis with Failure of Standard Treatment

K. Thorsen, N. Jessen, H. Grønbæk, 2017, Basic & clinical pharmacology & toxicology.

New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report

P. Ott, H. Grønbæk, I. Vogel, 2020, World journal of gastroenterology.

Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner.

D. Vitale, T. G. Belgard, B. Gloss, 2021, Cell systems.

The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study

T. Gregersen, K. Krogh, H. Grønbæk, 2018, Neuroendocrinology.

TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma

S. Hamilton-Dutoit, H. Grønbæk, N. Aagaard, 2020, Scandinavian journal of gastroenterology.

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients

M. Karsdal, A. Krag, H. Grønbæk, 2015, PloS one.

The influence of preconditioning on metabolic changes in the pig liver before, during, and after warm liver ischemia measured by microdialysis

P. Funch‐jensen, F. Mortensen, H. Grønbæk, 2009, Hepatology international.

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

S. Hamilton-Dutoit, H. Møller, K. Thorsen, 2016, Scandinavian journal of gastroenterology.

Increased ornithine decarboxylase activity in kidneys undergoing hypertrophy in experimental diabetes

H. Grønbæk, B. Richelsen, A. Flyvbjerg, 1992, Molecular and Cellular Endocrinology.

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.

H. Sorbye, H. Grønbæk, U. Knigge, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis

H. Møller, T. Sandahl, H. Grønbæk, 2012, Alimentary pharmacology & therapeutics.

A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

A. Kjaer, H. Grønbæk, P. Iversen, 2021, EJNMMI Research.

Vitamin B12 and its binding proteins in hepatocellular carcinoma and chronic liver diseases

P. Angus, H. Grønbæk, H. Vilstrup, 2014, Scandinavian journal of gastroenterology.

The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.

A. Tjønneland, L. Dragsted, A. Olsen, 2019, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial

A. Deshmukh, H. Grønbæk, F. Bendtsen, 2020, BMJ Open.

Cognitive impairment in stable Wilson disease across phenotype

T. Sandahl, P. Ott, H. Grønbæk, 2021, Metabolic Brain Disease.

Cognitive impairment in stable Wilson disease across phenotype

T. Sandahl, H. Grønbæk, H. Vilstrup, 2021, Metabolic brain disease.

Budd‐Chiari and inferior caval vein syndromes due to membranous obstruction of the liver veins: successful treatment with angioplasty and transcaval transjugular intrahepatic porto‐systemic shunt

H. Grønbæk, H. Vilstrup, S. Keiding, 2004, Scandinavian journal of gastroenterology.

Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls

A. Handberg, H. Grønbæk, S. Pedersen, 2017, International Journal of Obesity.

Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children

A. Handberg, H. Grønbæk, H. Vilstrup, 2016, European Journal of Clinical Nutrition.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

T. Berg, A. Mangia, J. Nattermann, 2016, Nature Communications.

MBOAT 7 rs 641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

T. Berg, A. Mangia, J. Nattermann, 2016 .

Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study

M. Karsdal, P. Olinga, H. Grønbæk, 2020, Clinical and translational gastroenterology.

Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism.

J. Frystyk, T. Sandahl, N. Jessen, 2012, Clinical nutrition.

Circulating mannan‐binding lectin, M‐, L‐, H‐ficolin and collectin‐liver‐1 levels in patients with acute liver failure

William M. Lee, S. Thiel, T. Sandahl, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects

F. Knop, H. Grønbæk, T. L. Laursen, 2019, World journal of hepatology.

Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions.

S. Hamilton-Dutoit, H. Grønbæk, H. Vilstrup, 2019, Clinics and research in hepatology and gastroenterology.

Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis

G. Baatrup, J. Dahlerup, H. Grønbæk, 2005, BMC gastroenterology.

Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art

J. Mortensen, H. Grønbæk, U. Knigge, 2016, Acta oncologica.

Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

T. Gregersen, K. Krogh, H. Grønbæk, 2011, Neuroendocrinology.

Metabolic effects of one-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults.

J. Holst, M. Gillum, L. Gether, 2021, European journal of endocrinology.

Selenium complexes in the anterior pituitary of rats exposed to L-selenomethionine

H. Grønbæk, O. Thorlacius-Ussing, 1990, Virchows Archiv. B, Cell pathology including molecular pathology.

Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections.

J. Frystyk, M. Bjerre, H. Grønbæk, 2010, World journal of hepatology.

Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting.

L. Skov, L. Iversen, A. Funding, 2017, Acta dermato-venereologica.

Alcoholic Hepatitis Markedly Decreases the Capacity for Urea Synthesis

H. Møller, H. Grønbæk, H. Vilstrup, 2016, PloS one.

Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.

H. Grønbæk, J. George, H. Vilstrup, 2014, World journal of hepatology.

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)

T. Sandahl, H. Grønbæk, E. Søndergaard, 2022, Diabetes.

A descriptive cross-sectional study of pain in patients with neuroendocrine tumors

N. Finnerup, H. Grønbæk, G. Dam, 2017, Scandinavian journal of gastroenterology.

Syddansk Universitet Antibody-Directed Glucocorticoid Targeting to CD 163 in M 2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes

S. Moestrup, H. Møller, H. Grønbæk, 2017 .

Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors

S. Laurberg, T. Gregersen, V. Schlageter, 2011, Scandinavian journal of gastroenterology.

Cell death markers in cirrhotic patients with acute decompensation

R. Moreau, R. Jalan, A. Gerbes, 2017 .

Isolated congenital hepatic fibrosis associated with TMEM67 mutations: report of a new genotype–phenotype relationship

S. Hamilton-Dutoit, P. Ott, H. Grønbæk, 2017, Clinical case reports.

Selenium in the central nervous system of rats exposed to 75-Sel-selenomethionine and sodium selenite

H. Grønbæk, O. Thorlacius-Ussing, 1992, Biological Trace Element Research.

Associations between the IGF system and inflammatory markers in inflammatory bowel disease

H. Grønbæk, M. Eivindson, 2006, Alimentary pharmacology & therapeutics.

A nationwide study of autoimmune liver diseases in the Faroe Islands: Incidence, prevalence, and causes of death 2004 - 2021

H. Grønbæk, K. Nielsen, Jóngerð Midjord, 2023, International journal of circumpolar health.

The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis

H. Møller, T. Sandahl, H. Grønbæk, 2016, Alimentary pharmacology & therapeutics.

The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease

T. Sandahl, P. Ott, H. Grønbæk, 2018 .

Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease

H. Grønbæk, H. Vilstrup, S. Keiding, 2011, Scandinavian journal of gastroenterology.

Cirrhosis and mortality risks of biopsy‐verified alcoholic pure steatosis and steatohepatitis: a nationwide registry‐based study

H. Grønbæk, H. Vilstrup, T. Deleuran, 2012, Alimentary pharmacology & therapeutics.

Personal Ventilation: from research to practical use

Arsen Krikor Melikov, Henning Grønbæk, Jan Bach Nielsen, 2007 .

The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation.

H. Møller, R. Jalan, H. Grønbæk, 2019, Journal of clinical and experimental hepatology.

Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center

A. Knudsen, P. Ott, H. Grønbæk, 2014, Indian Journal of Gastroenterology.

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

H. Sorbye, J. Mortensen, A. Sundin, 2023, Acta oncologica.

Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis

H. Grønbæk, H. Vilstrup, S. Keiding, 2004, Scandinavian journal of gastroenterology.

Effects of implementation of a national fast track clinical pathway for hepatocellular carcinoma in Western Denmark.

P. Ott, H. Grønbæk, H. Vilstrup, 2019, Journal of gastrointestinal and liver diseases : JGLD.

Contrast‐enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer

F. Mortensen, H. Grønbæk, M. Lund, 2016 .

Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.

T. Karlsen, A. Bergquist, E. Melum, 2023, Journal of hepatology.

Prognosis and staging of non-alcoholic fatty liver disease

H. Grønbæk, P. Jepsen, 2011, BMJ : British Medical Journal.

Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with (90)Y-DOTATOC: Associations with Risk Factors.

H. Grønbæk, P. Iversen, S. Kramer, 2015, Current radiopharmaceuticals.

Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor β receptor expression in experimental diabetes in rats

A. Logan, H. Grønbæk, A. Flyvbjerg, 2001, Diabetologia.

Exercise increases myocardial free fatty acid oxidation in subjects with metabolic dysfunction-associated fatty liver disease.

J. Frystyk, L. Gormsen, H. Grønbæk, 2023, Atherosclerosis.

The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis

H. Møller, P. Ott, H. Grønbæk, 2023, Hepatology communications.

Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis

H. Grønbæk, H. Vilstrup, M. Lauridsen, 2012, Metabolic Brain Disease.

Effects of lifestyle intervention on IGF-1, IGFBP-3, and insulin resistance in children with obesity with or without metabolic-associated fatty liver disease

J. Frystyk, H. Grønbæk, K. Kristensen, 2022, European Journal of Pediatrics.

Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single‐Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent

J. Holst, B. Hartmann, T. Sandahl, 2021, Clinical pharmacology and therapeutics.

Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders.

J. Trebicka, C. Bureau, H. Grønbæk, 2020, Alimentary pharmacology & therapeutics.

Soluble CD163: a marker molecule for monocyte/macrophage activity in disease

P. H. Petersen, S. Moestrup, H. Møller, 2002, Scandinavian journal of clinical and laboratory investigation. Supplementum.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

H. Sorbye, E. Hofsli, H. Grønbaek, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

1160O An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis

A. Haug, R. Hicks, H. Grønbæk, 2020 .

Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion.

Birgitte Lund Nielsen, R. Osterby, H. Grønbaek, 1999, Journal of hypertension.

Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children.

A. Handberg, H. Grønbaek, H. Grønbæk, 2010, European journal of endocrinology.

Omega‐3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega‐6 fatty acids

I. Brandslund, D. Hougaard, P. Munkholm, 2005, Alimentary pharmacology & therapeutics.

B. Bibby, H. Møller, H. Grønbæk, 2015 .

Table 1. Multiple Ordered Logistic Regression Analysis in Patients With HCV and HBV Infection

B. Bibby, H. Møller, H. Grønbæk, 2015 .

Creation of a Fistula Between the Hepatic Duct and the Gastric Lumen by way of Percutaneus Transhepatic Cholangiography: A Case Report

F. Mortensen, H. Grønbæk, M. Lauridsen, 2012, Journal of Gastrointestinal Cancer.

Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality

H. Grønbaek, H. Grønbæk, H. Vilstrup, 2022, Hepatology communications.

Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.

H. Grønbæk, J. George, H. Vilstrup, 2014, World journal of hepatology.

The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation

H. Møller, H. Grønbæk, S. Rittig, 2023, Bone Marrow Transplantation.

Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis.

A. de Gottardi, R. Moreau, J. Trebicka, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.